Annals of internal medicine

Semaglutide may increase maximum walking distance after 1 year in people with peripheral artery disease and type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

The study observed associations between cardiovascular health and specific endocrine factors.

  • Cardiovascular health may be influenced by various hormonal levels.
  • Endocrine factors could correlate with heart function metrics.
  • Preliminary findings suggest potential links between hormonal imbalances and cardiovascular risk.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosures: Disclosure forms are available with the article online.
PubMed

Related papers

Jun '25
Adding oral semaglutide to usual treatment lowers major heart and blood vessel problems in high-risk type 2 diabetes over about 4 years
top 2% journal
journal article
Oct '24
Study design and starting traits of STRIDE trial testing semaglutide in people with artery disease and type 2 diabetes
top 5% journal
cited by 19 papers
clinical trial protocol
Apr '25
Semaglutide's effects on walking ability in people with artery disease and type 2 diabetes
top 1% journal
cited by 55 papers
randomized controlled trial
Jun '25
Semaglutide’s benefits for artery disease symptoms vary with type 2 diabetes traits
top 1% journal
cited by 6 papers
randomized controlled trial
Sep '25
Weekly semaglutide improves liver inflammation and scarring in moderate to advanced fatty liver disease after 72 weeks
top 2% journal
journal article
Jul '25
Semaglutide linked to fewer limb problems in people with type 2 diabetes and artery disease or foot ulcers
top 5% journal
cited by 4 papers
observational study
Jul '25
How Tirzepatide, Liraglutide, and Semaglutide Compare in Lowering Heart Event Risks for People with Sleep Apnea and Type 2 Diabetes
top 10% journal
cited by 12 papers
comparative study
Jun '25
Semaglutide as an important medicine for managing combined heart, kidney, and metabolism problems
top 50% journal
cited by 10 papers
journal article
Sep '24
Semaglutide's effects on heart failure in people with diabetes and kidney disease in the FLOW trial
top 1% journal
cited by 96 papers
randomized controlled trial
Jul '25
Semaglutide's impact on survival in people with type 2 diabetes and chronic kidney disease
top 20% journal
cited by 1 paper
multicenter study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief